Volume 30, Number 6—June 2024
Research
Follow-Up Study of Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine Against All-Type and Serotype-Specific Invasive Pneumococcal Disease, Denmark
Katrine Finderup Nielsen1
, Lise Birk Nielsen1, Tine Dalby, Frederikke Kristensen Lomholt, Hans-Christian Slotved, Kurt Fuursted, Zitta Barrella Harboe, Charlotte Sværke Jørgensen, and Palle Valentiner-Branth
, Lise Birk Nielsen1, Tine Dalby, Frederikke Kristensen Lomholt, Hans-Christian Slotved, Kurt Fuursted, Zitta Barrella Harboe, Charlotte Sværke Jørgensen, and Palle Valentiner-Branth
Table 1
Patient characteristics according to vaccination status in follow-up study of effectiveness of PPSV23 vaccine against invasive pneumococcal disease, Denmark*
| Characteristic |
Study population at entry |
Study population at exit |
|
| Unvaccinated |
Vaccinated with PPSV23 during the study period |
||
| Total |
1,254,498 (100) |
288,383 |
966,115 |
| Sex | |||
| F | 668,726 (53) | 157,590 (55) | 511,136 (53) |
| M |
585,772 (47) |
130,793 (45) |
454,979 (47) |
| Age, y | |||
| Median (IQR) | 72 (67–78) | 74 (68–81) | 75 (70–81) |
| <75 | 760,980 (61) | 150,620 (52) | 436,070 (45) |
| 75–84 | 373,294 (30) | 91,009 (32) | 391,251 (41) |
| >85 |
120,224 (9) |
46,754 (16) |
138,794 (14) |
| Vaccination status | |||
| Received PCV7 or PCV13 before study entry | 19,035 (2) | 2,494 (1) | 16,541 (2) |
| Received PCV7 or PCV13 during follow-up | NA | 1,500 (1) | 15,558 (2) |
| Received influenza vaccine within 2 y before study entry | 645,980 (52) | 59,105 (21) | 530,467 (55) |
| Received of influenza vaccine during follow-up |
NA |
97,400 (34) |
937,489 (97) |
| No. underlying conditions† | |||
| 0 | 1,017,954 (81) | 204,788 (71) | 652,863 (68) |
| 1 | 198,611 (16) | 60,364 (21) | 231,957 (24) |
| 2 | 32,047 (3) | 17,334 (6) | 61,742 (6) |
| >3 |
5,886 (0) |
5,897 (2) |
19,553 (2) |
| Individual underlying conditions† | |||
| Myocardial infarction | 18,684 (1) | 4,433 (2) | 16,507 (2) |
| Congestive heart failure | 15,256 (1) | 7,624 (3) | 26,295 (3) |
| Peripheral vascular disease | 23,780 (2) | 8,761 (3) | 35,072 (4) |
| Cerebrovascular disease | 50,748 (4) | 16,028 (6) | 55,803 (6) |
| Dementia | 16,044 (1) | 7,354 (3) | 25,564 (3) |
| Chronic pulmonary disease | 24,074 (2) | 7,948 (3) | 36,996 (4) |
| Connective tissue disease | 10,765 (1) | 4,955 (2) | 23,406 (2) |
| Ulcer disease | 8,893 (1) | 2,693 (1) | 8,755 (1) |
| Mild liver disease | 3,512 (0) | 2,277 (1) | 6,328 (1) |
| Diabetes mellitus | 15,130 (1) | 3,699 (1) | 14,362 (1) |
| Hemiplegia | 621 (0) | 347 (0) | 1,407 (0) |
| Moderate/severe renal disease | 11,104 (1) | 6,404 (2) | 20,725 (2) |
| Diabetes with chronic complications | 7,301 (1) | 4,806 (2) | 16,603 (2) |
| Any tumor | 67,451 (5) | 29,878 (10) | 109,912 (11) |
| Leukemia | 715 (0) | 1,087 (0) | 4,157 (0) |
| Lymphoma | 1,471 (0) | 1,969 (1) | 7,998 (1) |
| Moderate/severe liver disease | 1,120 (0) | 823 (0) | 1,681 (0) |
| Metastatic solid tumor | 4,785 (0) | 3,271 (1) | 7,573 (1) |
| AIDS | 37 (0) | 159 (0) | 539 (0) |
*Values are no. (%) except as indicated. Persons vaccinated with PPSV23 during follow-up contributed to the analysis for both unvaccinated and vaccinated. IQR, interquartile range; NA, not applicable; PCV7, 7-valent pneumococcal conjugate vaccine; PCV13, 13-valent pneumococcal conjugate vaccine; PPSV23, 23-valent polysaccharide pneumococcal vaccine. †Within 5 y before study entry (1st column) or within 5 y from end of follow-up (2nd and 3rd columns).
1These authors contributed equally to this article.
Page created: April 10, 2024
Page updated: May 22, 2024
Page reviewed: May 22, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.